


PRODUCT INFORMATION



Avacopan

Item No. 36639

CAS Registry No.: 1346623-17-3
Formal Name: (2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]-3-piperidinecarboxamide
Synonym: CCX168
MF: C₃₃H₃₅F₄N₃O₂
FW: 581.6
Purity: ≥95% (mixture of isomers)
UV/Vis.: λ_{max}: 252 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Avacopan is supplied as a solid. A stock solution may be made by dissolving the avacopan in the solvent of choice, which should be purged with an inert gas. Avacopan is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of avacopan in these solvents is approximately 3, 5, and 12 mg/ml, respectively.

Description

Avacopan is an antagonist of the complement 5a₁ (C5a₁) receptor (IC₅₀ = 0.1 nM).¹ It is selective for C5a₁ over the C5a₂ receptor and chemokine-like receptor 2 (CMKLR2), also known as chemerin receptor 2 or GPR1 (IC₅₀s = >10,000 nM for both), as well as the C3a receptor, CMKLR1, and formyl peptide receptor 1 (FPR1; IC₅₀s = >10,000 nM for all), and over panels of 18 chemokine receptors (IC₅₀s = ≥6,700 nM for all), 54 other receptors at 10 μM, and five cytochrome P450 (CYP) isoforms (IC₅₀s = >10,000 nM for all). Avacopan (50 nM) reduces the migration of isolated cynomolgus monkey neutrophils. It also reduces C5a-induced increases in neutrophil cell surface levels of CD11b in whole blood isolated from mice with a knock-in of human C5AR1, the gene encoding the C5a₁ receptor, when used at concentrations of 10 and 100 nM or when administered at doses of 0.075 or 0.15 mg/kg. Formulations containing avacopan have been used in the adjunctive treatment of severe vasculitis associated with anti-neutrophil cytoplasmic autoantibodies (ANCA).

Reference

1. Bekker, P., Dairaghi, D., Seitz, L., *et al.* Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. *PLoS One* **11**(10), e0164646 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/25/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM